IPPRA / Grant Monitor

2026-07-07
← Board

Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)

PAR-25-225 · National Institutes of Health

biomedical clinical public health Health

Closes
2027-10-20 · 470 d
Award ceiling
Award floor
Program funding
Expected awards
Cost sharing
No
Posted
2024-11-04
Instrument
Grant
Characterization · gpt-5.4-mini · 2026-07-07

This NIH R61/R33 supports pharmacodynamic, pharmacokinetic, and in vivo efficacy studies of therapeutic agents for neurological or neuromuscular disorders within NINDS mission areas to advance them toward later translational development.

Funds
applied research
University
direct
physical sciences
minor
engineering
minor
life biomedical
central
computational data
minor

⚑ Clinical Trial Not Allowed · Foreign organizations are eligible · Supports translational preclinical development rather than clinical studies

Unit fits — one characterization, each unit's own rules

Physical Sciences & Engineering (demo) 55 good technical depth: minor; funds applied research
IPPRA 45 partial peripheral portfolio topic: public_health; social/behavioral work is none; funds applied research; biomedical core — IPPRA health lane is communication/crisis/policy (capped); capped at 45 (limited social-science role)
Tom Love Innovation Hub 30 weak funds applied research; deep-tech content

Description

Reissue PAR-21-122. This NOFO provides funding to conduct pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further development to treat neurological or neuromuscular disorders that fall under the NINDS mission. Therapeutic agents include small molecules, biologics or biotechnology-derived products. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the Blueprint Neurotherapeutics Network or other translational programs.

Eligibility

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Apply

View on Grants.gov → CONTACT: National Institutes of Health <grantsinfo@nih.gov>

Proposal brief SEE AN EXAMPLE →

A one-page internal memo: fit assessment, submission requirements, document scaffold, and next steps dated back from the deadline — tailored to your project idea if you add one.

ONE LLM CALL (~1¢) · CACHED · REQUIRES STAFF KEY

Proposal shell · National Institutes of Health conventions SEE AN NIH EXAMPLE →

Funder-faithful document skeletons — National Institutes of Health's document set with section headings, page limits, reviewer guidance, and writing prompts; add a project idea to get [DRAFT] starter bullets. Download as .md for Word or Overleaf.

ONE LLM CALL (~2-3¢) · CACHED · SCAFFOLDING, NOT GHOSTWRITING